Skip to main content

Table 1 GRADE evaluation of placebo-controlled studies evaluating efficacy and tolerability of onabotA

From: Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation

Studies (participants)

Outcome

Comparison

Type

Quality

Effect size

GRADE quality of evidence

Direction

Strength

Comment

Dodick (1384)

Headache days

OnabotA 155 U–195 U versus placebo

R

−1

0

Moderate

For

Strong

Quality points deducted for risk of bias (−1)

Diener (2436)

Adverse events

OnabotA 75 U–260 U versus placebo

R

-1

+ 1

High

For

Strong

Quality points deducted for risk of bias (−1). Effect size point added for small frequency of AE

  1. The Dodick paper [11] was a pooled analysis of the Aurora [4] and 2010 Diener [5] studies. The 2014 Diener paper [19] was a pooled analysis of two phase 2 studies in chronic daily headache [20, 21] and the two PREEMPT studies [4, 5]. Type: R randomized controlled trial